Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Hims & Hers Health (HIMS)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Summit Therapeutics (SMMT – Research Report) and Hims & Hers Health (HIMS – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Summit Therapeutics (SMMT)
Citi analyst Yigal Nochomovitz maintained a Buy rating on Summit Therapeutics today and set a price target of $40.00. The company’s shares closed last Monday at $16.09.
According to TipRanks.com, Nochomovitz is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Summit Therapeutics with a $35.00 average price target, representing a 122.2% upside. In a report released today, TipRanks – Google also upgraded the stock to Buy with a $18.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Hims & Hers Health (HIMS)
Citi analyst Daniel Grosslight reiterated a Sell rating on Hims & Hers Health today and set a price target of $13.25. The company’s shares closed last Monday at $15.51, close to its 52-week low of $11.20.
According to TipRanks.com, Grosslight is a 3-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Hims & Hers Health with a $32.03 average price target, implying a 102.8% upside from current levels. In a report issued on February 19, Bank of America Securities also maintained a Sell rating on the stock with a $13.00 price target.
